CDZ 173

Drug Profile

CDZ 173

Alternative Names: CDZ173

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase II Sjogren's syndrome

Most Recent Events

  • 26 May 2017 Novartis prematurely ends a phase II trial in Sjogren's syndrome in Poland (EudraCT2014-004616-12)
  • 17 May 2017 Novartis completes a phase II trial in Sjogren's syndrome (In adults, In the elderly) in Germany and Hungary (NCT02775916) (EudraCT2014-004616-12)
  • 08 Aug 2016 Novartis Pharmaceuticals plans a phase II/III extension trial for Immunodeficiency disorders (In adolescents, In adults) in USA, Netherlands, Czech Republic, United Kingdom, Ireland and Italy (PO) (NCT02859727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top